Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

LONDON (Reuters) - For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.

Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal
Read More


Bagikan Berita Ini